Published Date: 07/10/2023
Expiration Date: 04/17/2026
Training for New York State (NYS) medical providers on hepatitis C virus (HCV) resistance testing is needed as the landscape of HCV resistance to direct-acting antivirals (DAAs) is evolving. This activity will increase New York State providers’ knowledge on HCV resistance testing, including when resistance testing is necessary and how to interpret and act on resistance testing results, in order to ensure that providers can effectively treat patients with HCV.
David Wyles, M.D., FIDSA, is a graduate of Northwestern Univeristy Feinberg School of Medicine and currently Professor of Medicine in the Division of Infectious Diseases at the University of Colorado and Chief of the Division of Infectious Diseases at Denver Health Medical Center. Dr. Wyles’ research interests center on viral hepatitis including: the conduct of clinical trials with novel therapeutic for HBV and HCV, HCV drug resistance/retreatment and the treatment of viral hepatitis in the setting of HIV co-infection and in underserved populations. During the COVID-19 pandemic Dr. Wyles has also been involved in clinical trials of novel therapeutics for hospitalized patients with severe COVID-19.
He was an inaugural member of the AASLD/IDSA HCV guidelines panel is also a member of the International Antiviral Society – USA Hepatitis Advisory Board. He is a current member of the ACTG Hepatitis transformative science group